Nasdaq

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ...
Seeking Alpha

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients two years of age ...
Morningstar

First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS

CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company’s open-label extension study in MELAS (Mitochondrial ...
Seeking Alpha

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – CUPERTINO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (RVPH) (“Reviva” ...
Business Insider

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause ...
Morningstar

Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior

247 patients (mean age 14.3±7.6 years) were enrolled from study sites in North America, Europe, and Australia, with a median fenfluramine exposure of 364 days (range: 19–537) and a mean daily dose of ...
Cure Today

Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia

Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...
Business Wire

Alzprotect Announces Supportive Results from Open-Label Extension of Phase 2a Study for Progressive Supranuclear Palsy (PSP)

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...
Healio

Long-term data on selexipag for PAH reveal 60% survival rate at 10 years

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...
Medscape

CIDP Benefits Persist in Efgartigimod Open-Label Extension

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...